RecruitingNot ApplicableNCT05268887

High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease

Acute Treatment of Parkinson's Disease With Gamma Frequency Stimulation

Sponsor

Massachusetts Institute of Technology

Enrollment

40 participants

Start Date

Feb 9, 2022

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.

Eligibility

Min Age: 45 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a device that delivers flickering light, sound, and gentle vibration at a specific frequency (40 Hz) can improve movement and thinking problems in people with Parkinson's disease. **You may be eligible if...** - You have been diagnosed with idiopathic (typical) Parkinson's disease by a specialist - Your Parkinson's is at a moderate stage (Hoehn & Yahr stage 2 or 3) - You score 26 or higher on a memory/thinking test (MoCA) - You are between 45 and 90 years old - You are fluent in English - Your Parkinson's medication dose has been stable for at least 1 month - You have had a brain CT or MRI to rule out other causes **You may NOT be eligible if...** - You have significant memory or cognitive impairment (MoCA below 26) - You have a history of seizures or photosensitive epilepsy - Your Parkinson's stage is very mild (stage 1) or very severe (stage 4–5) - You are not fluent in English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.